China Medical System Holdings invests in VAXIMM
VAXIMM AG, a company focused on developing oral T-cell immunotherapies, entered into development and commercialization collaboration agreement with and received an equity investment by China Medical System Holdings Limited (CMS) (HKSE:0867). VAXIMM is a privately held biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. CMS is a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China.
VISCHER AG advises Vaximm AG regarding the equity Investment. The team is led by Matthias Staehelin (Partner) with Angelo Imperiale (Associate) both Corporate.